The Chicago Entrepreneur

[stock-market-ticker symbols="AAPL;MSFT;GOOG;HPQ;^SPX;^DJI;LSE:BAG" stockExchange="NYSENasdaq" width="100%" palette="financial-light"]
Menu
Business

Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda’s patent expiration in 2028.

Previous post Comcast is set to report earnings before the bell. Here’s what Wall Street expects
Next post Royal Caribbean’s stock rallied toward a record after a big profit beat and raised outlook, as cruise demand remained ‘very robust’

More Stories